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Couples wishing to achieve or avoid pregnancy can now use
an electronic hormonal fertility monitor to aid home fertility
monitoring. The Clearplan Easy Fertility Monitor (CPFM) is a
handheld monitor designed to help couples achieve pregnancy.
It provides information on three levels of fertility (low, high, and
peak) based on urinary threshold levels of estrogen and luteinizing hormone (LH). The monitor can be used as an aid to avoid
pregnancy when used with another marker of fertility. We conducted an efficacy study co determine che effectiveness of using the
monitor along with cervical mucus monitoring with 215 couples
seeking co avoid pregnancy and found a correct-use unintended
pregnancy rate of 2.0% per annum and a total pregnancy race of
13.0% per annum. These same couples rated the monitor easy to
use and helpful based on a ten-item survey. Overall, the monitor
is not perfect, but can be useful for couples who wish to have an
objective device for fertility monitoring.

n 1990, Carl Djerassi, one of the developers of the first hormonal contraceptive pill, published an article in Science magazine stating that in the future there will be what he called Jet
Age natural family planning (NFP) (Djerassi 1990). In the article,
he described a method of NFP whereby women would be able to
measure reproductive hormones in their urine to estimate the fertile phase of the menstrual cycle. Six years later, Unipath scientists
introduced a handheld fertility monitor, called Persona, which was
designed to read test strips impregnated with antibodies from two
reproductive hormones (estrone 3 glucuronide and luteinizing hormone, i.e., E3G and LH) and provide the user with an indication
of fertility (with a red light) and infertility (with a green light) (May
1997). A prototype of Persona was tested as a contraceptive device in
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Europe and, with an adjustment of its internal algorithm, is now sold
in Europe but not in the United States.
A similar device called ClearPlan (or ClearBlue) Easy Fertility
Monitor (CPFM) is sold in the United States as a device to help couples achieve pregnancy (May 2001; Spieler and Collins 2001). Like
Persona, the CPFM is a handheld device that measures threshold
levels of urinary E3G and LH. However, unlike Persona, the CPFM
provides three levels of fertility-low, high (based on reaching a
threshold of E3G), and peak fertility (based on reaching a threshold
of urinary LH) (May 2001; Unipath Diagnostics 2001). Since the
device is designed to enhance the ability to achieve pregnancy, it
does not always cover the beginning of the fertile phase of the menstrual cycle. To be used as a device for avoiding pregnancy, not only
does it need to be "used in reverse" (i.e., avoiding intercourse on the
high and peak days) but it also needs to be used along with another
marker for the beginning and sometimes end of the fertile phase.
The purpose of this paper is to provide evidence for the usefulness of the CPFM as an aid for avoiding pregnancy when used with
another marker of fertility. In order to accomplish this evidence will
be provided for: ( 1) the accuracy of the CPFM, (2) the effectiveness
of the CPFM when used along with cervical mucus monitoring as
a means to avoid pregnancy, and (3) evidence for satisfaction with
and ease of use of the CPFM. The satisfaction and ease-of-use results
include both quantitative and qualitative data. The conclusion will
illustrate how the monitor can be used effectively for special reproductive circumstances, such as the anovulatory state of breastfeeding,
long menstrual cycles, and peri-menopause.
EVIDENCE FOR ACCURACY OF THE CPFM

Accuracy data for the CPFM comes from the manufacturer and two
independent studies, one by researchers in Germany and the other
by researchers in Japan. The CPFM is designed to detect the rising
level of E3G and the surge in urinary LH. The CPFM is based on
urinary hormonal immunoassay techniques. Detection of urinary
metabolites of urinary estradiol (E3G) has been recognized by the
World Health Organization (WHO) as a reliable marker for the beginning of the fertile phase of the menstrual cycle (Spieler and Collins 2001). Product testing has shown the ClearBlue monitor to be
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98.8% accurate in detecting the LH surge. The CPFM detected the
LH surge in 169 of 171 cycles from 88 women, in agreement with a
quantitative radio immunoassay for LH (Unipath Diagnostics 2001).
In a study with 90 women who each used the CPF M for 1-4 cycles,
in 352 cycles with an LH surge, the first day of high fertility (i.e., the
day of the first rise in E3G) was 3.01 ± 2.33 days before the LH surge
(May 2001; Unipath Diagnostics 2001).
German researchers conducted an independent study to determine
the accuracy of the CPFM (Behre et al. 2000). They monitored 53
female volunteers to detect daily serum levels of LH and estradiol
and employed transvaginal ultrasound to ascertain the precise day
of ovulation. The 53 women contributed 150 cycles of data with use
of the CPFM, of which one cycle was determined to be anovulatory.
Of the remaining 149 cycles, there were 135 cycles (90.6%) in which
the CPFM detected an LH surge and there was an ultrasound-confirmed ovulation. In those 135 cycles, ovulation occurred 97.0% of
the time during a three-day period that included the two "peak" days
plus the next day "high" on the CPFM. There were no ultrasounddetected ovulations before the monitor "peak" days. The researchers
also found that, in 92% of the cycles, the first "high" reading on the
monitor coincided with the serum estradiol rise day.
Another study with 30 healthy female volunteers showed that a
Japanese-made version of the CPFM, called the Clearview Primera
Fertility Monitor (made by Mitsui Pharmaceuticals, Inc., in Tokyo,
Japan), indicated up to five days of "high" fertility readings in 58.6%
of the cycles (i.e., 17 out of 29 cycles) before the CPFM "peak" reading and in 82.8% of the cycles (i.e., 24 of 29 cycles) before a laboratory determined urinary LH peak (Tanabe et al. 2001). The authors
of that study concluded that the device will allow couples to use the
information to time intercourse for the best prospects of achieving
pregnancy.
EFFICACY OF THE CPFM AS AN AID TO NFP

No published studies have reported on the efficacy of the CPFM as
an aid to avoid pregnancy. However, researchers from Germany, Ireland, and the United Kingdom collaborated on a study to determine
the effectiveness of a prototype of the Persona monitor (Bonnar et al.
1999). This study is relevant because the early prototype of the Per-
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sona had the same threshold levels for detecting E3G and LH as the
current CPFM. The Persona study involved 710 female volunteers
(median age 30 years, with regular menstrual cycles) who were asked
to use the fertility monitor (without any formal training) for the
purpose of avoiding pregnancy for a one-year period. At completion
of the study and 7,209 cycles of use, there were 67 method-related
pregnancies (i.e., pregnancies that resulted from having intercourse
on a "green light" day), 92 user-related pregnancies (intercourse on
"red light" days), and 3 pregnancies of uncertain timing. A 13-cycle
life table analysis yielded a method (i.e., correct use) pregnancy rate
of 12.1 %. Theoretically, the algorithm used in the current CPFM
alone would provide this level of efficacy if used in reverse without
other markers for the beginning and end of the fertile window.
MARQUETTE EFFICACY STUDY OF THE CPFM

In 2001, researchers at Marquette University initiated an efficacy
study of using the CPFM as an aid to NFP for the purpose of avoiding pregnancy (Fehring et al. 2007). A method was developed in
which the use of the CPFM was paired with self-observation of cervical mucus. Cervical mucus (both appearance and sensation) was
rated on a 1-8 scale, with 1 being no mucus and dry sensation, and
8 being wet and slippery sensation. The beginning of the fertile phase
was either the presence of mucus or a high reading on the monitor
(whichever came first), and the end of fertility was three full days
past the peak on the monitor.
Our study enrolled 225 couples from four cities-Atlanta, Madison, Milwaukee, and St. Louis. Of the 225 couples, 195 contributed
data for the analysis, and 30 were lost to follow-up and did not return
data or the monitors. Mean age of the 195 female participants was
29.4 years (SD= 5.8, range 19-42), and mean age of the male partners was 31. l years (SD = 6.2; range 18-49). The participants were
primarily Caucasian, Catholic, and at least high-school educated,
had a mean of 1.4 children, and had combined household incomes
greater than $50,000. None of the participants were on hormonal
contraception or breastfeeding for at least three months before enrolling in the study. All participants agreed to avoid pregnancy with
use of the CPFM for 12 months.
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There were a total of 22 unintended pregnancies, of which three
occurred with correct use, and a total of 1,795 documented months
of use. The 12-month correct-use survival rate was 0.98, meaning an
unintended pregnancy rate of2.0 per annum (95% CI= 0.96-1.00).
The total (typical use) survival rate at 12 months was 0.86, meaning
an unintended pregnancy rate of 14.0 per annum (95% CI = 0.820.94). After that study was completed, another 20 couples met the
criteria for the study and were added to the data set for this paper. So
we now had a total of 215 couples and 22 unintended pregnancies,
of which three were achieved with correct use, and a total of 1,850
documented months of use. The correct-use unintended pregnancy
rate was still 2.0 per annum with a 98% effectiveness and a total use
pregnancy rate of 13.0%, or an 87% survival rate effectiveness. (See
Table 1.)
Table 1: Twelve-Month Correct and Typical Unintended Pregnancy Rates with
Use of the CPFM Plus Cervical Mucus Monitoring (N = 215 couples)

Correct Use
Rare

#

Preg

Preg

Typical Use
Rate

3 months

1

0.995

8

0.962

6 months

0

0.995

5

0.922

9 months

1

0.988

4

0.896

12 months

1

0.980

5

0.871

Total

3

Months of Use

#

22

The 215 participants contributed a mean of8.6 months of use (SD=
3.9; median of 11 months), and 122 (56.7%) remained in the study
for the agreed 12 months. Of the remaining 93 participants, 30 were
lost to follow-up, 19 left to achieve a pregnancy, 18 left for personal
reasons, and 3 left for health reasons. Of the 19 participants who intended to achieve a pregnancy, 12 did so in the first cycle of trying.

Human Fertility: Where Faith & Science Meet

130

SATISFACTION WITH THE USE OF THE CPFM AS AN
AID TO AVOID PREGNANCY

In order to determine the satisfaction and usefulness of the CPFM,
we mailed a I 0-item satisfaction survey to the 195 participating
couples of our prospective study. The IO-item survey was a shortened form of a satisfaction questionnaire developed by Severy for
evaluating the Persona fertility monitor (Severy 2001). The l 0 items
are ranked on a scale from 1 to 7, with bipolar negative and positive
adjectives. (See Table 2 for the content of each item.)
The survey was mailed anonymously to the 195 couples (husband
and wife) in the study after completion of the efficacy phase. Of the
195 surveys mailed, 65 were returned with undeliverable addresses.
Of the 130 couples who received the questionnaires, 77 of the female
forms (59.2%) and 71 of the male forms (54.6%) were returned.
As seen in Table 2, the mean scores for the women ranged from
Table 2: Ease of Use and Satisfaction with the ClearPlan Easy Fertility Monitor*

Female (N = 77)

Item

M ale (N = 70)

Mean

SD

M ean

SD

Ease of including monitor in daily routine

5.70

1.48

5.87

1.35

Ease of performing urine rest

6.23

l.02

6.1 3

1.33

Understanding monitor information

6.55

0.78

6.21

1.13

Overall opinion of CPFM

6.15

l.00

5.93

1.28

CPFM increased ability to avoid pregnanq

5.99

l.46

6.01

1.39

CPFM decreased anxiety about pregnancy

5.68

1.42

5.67

1.34

Ease of using the CPFM

6.11

1.04

5.86

J.21

How do you like the CPFM

5.92

1.30

5.89

J.28

Compared to other methods, how improved

6.25

1.6 I

6.07

J.69

Chances of avoiding pregnancy

5.98

1.23

6. 10

J.09

* Rating based on

1-7 scale, with 7 being the highest rared score for each item.

5.68 to 6.55 and for the men ranged 5.67 to 6.21. The highest rated
item of the IO for both the women and the men was "understand-
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ing the information the monitor provided." The lowest ranked item
for both the women and the men was "to what degree has the use of
the CPFM has decreased your anxiety about becoming pregnant."
Overall, ease of use, information provided, and the ability to use
the monitor to avoid pregnancy were ranked very high by both the
husbands and the wives.
The survey also included a section for open-ended comments.
There were comments from 25 of the respondents. The most frequent responses were (1) the test strips were too expensive, (2) the
monitor did not always provide a warning of peak, and (3) the monitor was useful in objectively defining the peak day. Following is an
example response saying that the test strips were too expensive:
After the birth ofour third child we used the monitor briefly to avoid
pregnancy, however, it was difficult to obtain the test sticks at various
Walgreen's in our area. Additionally, the cost of the sticks was a fact to
continue with the monitor.

Following is an example from another couple:
The sticks are too expensive and we have found another method using
saliva that we like better.

Following is an example response saying that there was no warning
of the peak of fertility:
The monitor generally did not register before my p eak ovulation day. I
had to rely completely on mucous observations pre peak. It was helpful
identifying my peak day.

Following is an example from another couple:
Two days ago the monitor read a peak with no sign by mucus or monitor ofrising fertility.

Following is an example response saying that the monitor helped to
clarify the peak:
Even if I saw mucus post peak I knew for sure I had ovulated thus
reducing confasion.

Following is an example from another couple:
It only helps make rhythm a little clearer because it marks a certain
ovulation.
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DISCUSSION OF EFFICACY AND SATISFACTION

Researchers have recommended using urinary hormonal markers
(i.e., urinary metabolites of estrogen, progesterone, and LH) as indicators of the fertile phase for helping women/couples to avoid pregnancy (Martinez et al. 1995; Martinez 1997; Crosignani and Rubin
2000). However, there have been no published studies on how effective urinary LH indicators or the use of the CPFM could be to
help women/couples avoid pregnancy. The current study is the first
efficacy study of using the CPFM as an adjunct to self-observation of
cervical mucus as a means to avoid pregnancy.
The low correct-use unintended pregnancy rate of 2% found is
similar to efficacy rates found with other NFP methods. Like other
NFP methods, the CPFM plus cervical mucus self-observation overestimates the fertile phase. Most of the overestimation in this study
was due to estimating fertility by use of self-observation of cervical
mucus (Fehring, Raviele, and Schneider 2004). The mean number
of days of fertility, as estimated by self-evaluation of cervical mucus
based on the 1,300 NFP charts collected for this study, was 11.1 (SD
= 3.7), and the total days of fertility estimated by the CPFM was 6.1
(SD= 3.2).
Although the Marquette researchers hoped to have a lower unintended pregnancy rate, the 12- 14% per annum unintended pregnancy rate found in this study was not unexpected. This rate is lower
than the overall typical unintended pregnancy rate of 20-25% for
NFP methods as reported in the literature (Trussell 2004). The lower
typical pregnancy rate could be because of the homogenous characteristics of the sample, the higher education and social class of the
sample used in this study, or the accuracy and ease of use of the fertility monitor.
In an earlier effectiveness study of a mucus-only method at Marquette University, researchers found a correct-use 12-month unintended pregnancy rate of 2.0 and a use-effectiveness rate of 15.2
among 242 couples (Fehring, Lawrence, and Philpot 1994). In comparison, the current study had a use-effectiveness pregnancy rate of
11.2%. The participants for both of these studies were demographically similar. The correct-use rates are similar, but the use rates from
the monitor plus mucus seem to be slightly better. So a question
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could be asked whether the monitor actually adds to the efficacy of
using mucus-only NFP methods. This question could be answered
only by a randomized comparison study.
Comparison of the results of this study could also be made with
two other recent efficacy studies of NFP methods-a calendar-based
method called the Standard Days Method (SOM) and a simplified
version of cervical mucus monitoring called the TwoDay Method
(TOM) (Arevalo, Jennings, and Sinai 2002; Arevalo et al. 2004).
The correct use per annum pregnancy rates for the SOM and TOM
were 5.60 and 4.50, respectively, and the typical or total pregnancy
rates were 12.0 and 14.0, respectively. Although the correct-use unintended pregnancy rate of 2.0% for the current study is lower than
these two studies, the differences could well be due to the poorer
and less educated participants in the SOM and TOM studies and/or
to the accuracy of the fertility monitor. The typical-use unintended
pregnancy rates of the current study are similar to the SOM and
TOM rates. However, the accuracy of the CPFM used in the current
study might be lost when it is paired with cervical mucus observations. Furthermore, having two markers of fertility made the use of
the CPFM plus mucus method much more complex than the simpler instructions for use of the SOM and TOM. Finally, the pregnancy rates for the SOM and TOM rates were determined on cycles
of use rather than months of use.
RELATED SATISFACTION AND EASE-OF-USE STUDIES

In a similar study on the acceptability of the CPFM, Severy (2001)
assessed the acceptability of the Persona monitor with 220 U.S.
women who recorded their acceptability and ease of use of the fertility device on a 7-point scale, with 1 being the least acceptable (and
most difficult to use) and 7 the most acceptable (and the easiest to
use). The 220 women were between the ages of 18 and 35, were in
monogamous relationships, were sexually active, were not intending
to have a child in the next year, and used the device for at least six
months. The mean rating of "ease of use," like in the current study,
was around 6, and the mean acceptability score was close to 6. The
investigator concluded that the Persona fertility monitor was highly
acceptable to volunteer couples and that the monitor had a positive
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effect on the women's reproductive functioning, the women's health,
and the couples' relationships.
In a related study, researchers from Family Health International
and the University of Florida conducted a study to determine the
psychological impact of using the CPFM with 52 couples from Florida and North Carolina who used the monitor for four consecutive
cycles to achieve pregnancy ( Severy et al. 2006). The couples also
were provided with a multiple-item, paper-and-pencil tool to measure dimensions of acceptability for their family planning method.
Acceptability of the monitor and having fertility-focused intercourse
were more favorable at baseline among the couples who eventually
achieved a pregnancy. For couples who did not achieve pregnancy,
acceptability declined over time, and relationships became more
strained.
The researchers concluded that their research findings suggested
that fertility monitoring does not have a negative influence and m ay
even have a positive influence on the couples' relationship, in p articular in enhancing communication. Although gaining knowledge
of fertility initially helped to keep stress and anxiety at a minimum,
stress and anxiety entered the relationship for couples that did n ot
achieve a pregnancy.
Finally, Severy and Robinson (2004) also found high acceptability
and reproductive knowledge among 60 couple users of the CPF M
across time (i.e., 13 cycles of use). The acceptability was higher
among couples who became pregnant within the first three months
of use. There have been no studies to determine the acceptability and
ease of use of the CBFM as a device to monitor fertility and avoid
pregnancy along with a double-check of the fertile window (i.e. , a
fertility algorithm).
LIMITATIONS IN USING THE CPFM
PLUS MUCUS OBSERVATION

The obvious limitation of the efficacy portion of this study was that
the sample was not compared with a random selection of participants using another method of family planning. Therefore, the results could be influenced by many factors , including biases of the
researchers and clinicians contributing to the study (Grimes et al.
2005; Trussell 2004).
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Another limitation is that use of two markers of fertility adds to
the complexity of teaching and using this method of NFP. Furthermore, at times the two markers of fertility confused the participants
(e.g., when there was a low reading on the monitor and cervical mucus present, when the peak in the monitor and the peak in mucus did
not coincide, or when there was no peak reading for the monitor).
The confusion with the two markers was also reflected in the satisfaction results when several couples mentioned they did not experience
any high days before the peak reading of the monitor. Some couples
would incorrectly ignore the mucus reading when they had a low
reading on the monitor.
Although the couple participants agreed to avoid pregnancy for 12
months with the use of the monitor and mucus observations, some
of the young couples discontinued the study prematurely to achieve
a pregnancy or started to test the ends of the estimated fertile window without declaring that they were trying to achieve a pregnancy.
We have observed that the decision to achieve a pregnancy does not
always begin with a 100% effort. Unintended intercourse patterns
reveal that there is often a first testing of the ends of the estimated
fertile phase. Furthermore, although the frequency of intercourse,
among the participants, was similar to previous studies, there was an
underreporting of intercourse during the fertile time. This was apparent when a number of participants would reveal this several months
after the pregnancy interview. The average frequency of intercourse
per cycle for this study was 3.85 (SD= 3.32; range 1-24), but many
of the cycles (16%) had missing data or no recorded intercourse due
to uneasiness of sharing that information.
RECOMMENDATIONS

A conservative recommendation from this study would be that
when using both cervical mucus monitoring plus the CBFM, couples should be consistent in monitoring both markers and avoiding
intercourse when either marker indicates a fertile day. Waiting for
three full days after the peak in the monitor or mucus (i.e., resuming intercourse on the evening of the fourth day past either peak) is
recommended. The intercourse patterns in this study showed that
unintended pregnancies tended to occur at the end and just outside of the end of the estimated fertile phase. In fact, with 13 of the
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unintended pregnancies, intercourse occurred on either the third or
fourth day past the last peak reading on the monitor.
Another recommendation is to simplify the method and to use
only the monitor as an indicator of fertility along with a simple algorithm (Fehring 2005). The algorithm is based on using the earliest
peak on the monitor from the last six cycles of charting minus six
days as a double-check for the beginning of the fertile phase. European researchers have demonstrated good efficacy results with a double-check method of NFP using the basal body temperature shift ,
cervical mucus, and a calendar-based formula (Frank-Hermann et
al. 2005). Hopefully, simplifying the use of the monitor as a means
to avoid pregnancy would make it easier for the couple and help to
lower unintended pregnancies.
A final recommendation is to conduct a randomized control trial
of the CPFM comparing the recommended fertility algorithm with
the use of cervical mucus alone as a method of avoiding pregnancy.
The monitor could also be compared with the use of basal body temperature (BBT) as a marker of fertility or other developed methods
of NFP.
USE OF THE CPFM WITH SPECIAL CIRCUMSTANCES

In order to be useful as a method of NFP, the CPFM needs to be
able to adapt to, and provide estimates for, fertility during special reproductive circumstances. These special circumstances include long
cycles, breastfeeding, and the peri-menopausal years. The CPFM is
designed to be able to track menstrual cycles that vary from 21 to 42
days in length. This variability in length should capture most menstrual cycles, since at least 95% fall within 21-35 days in length
(Fehring et al. 2006). However, menstrual cycles longer than that
pose a problem. When menstrual cycles are longer than that on a
consistent basis, we have the women retrigger the monitor and fast
forward to day 5. The monitor will then test for elevated levels o f
E3G and LH for the next 20 days.
Marquette University researchers have designed a protocol for
women who are breastfeeding and not ovulating. The protocol entails creating artificial 26-day cycles. To do this, a woman fast forwards the monitor to day 5 every 20 days. The monitor starts asking
for a test on day 6 and continues testing for E3G and LH for the
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next 20 days. The woman creates these artificial 26-day cycles until a
peak reading is recorded followed by a menses. Results of using the
protocol were recently reported from the first 10 breastfeeding users
(Fehring, Schneider, and Barron, 2005). The researchers found that
only 17% of the days during the ovulatory breastfeeding duration
leading to the first menses were considered fertile by the monitor,
compared with the estimated 50% of the days by self-observation
of cervical mucus (t = 3.64, p < 0.01). Furthermore, the peak (LH
reading) gave a clear estimate of the first ovulation before the first
menses.
Although the Marquette researchers do not have a protocol developed for women experiencing peri-menopausal variability, they have
been tracking the use of the monitor with women who fall into this
category of fertility. For the most part, the monitor is able to track
the variability in length and estimated time of fertility. When the
variability between long and short cycles gets too great, the monitor
might miss the fertile phase in the very short or long cycles. However, when this happens, the woman is probably not fertile. Taffe
and Dennerstein (2002) have demonstrated that once the running
range between the longest and shortest menstrual cycle among perimenopausal women is greater than 42 days, there will be fewer than
20 menstrual cycles left.
CONCLUSION

Although the CPFM was designed for couples to achieve pregnancy,
when used along with another marker of fertility, it can be a very effective means of avoiding pregnancy. Marquette University researchers found that it is at least as effective as, if not more effective than,
current NFP methods. For the most part, couples using the monitor
found that it was easy to use, provided good information about the
menstrual cycle, and helped to objectively estimate the fertile phase.
Further studies need to be conducted to compare use of the monitor
to avoid pregnancy with other methods of NFP. Finally, simplification of using the monitor as a method to avoid pregnancy could be
accomplished by using a simple fertility algorithm to have a doublecheck for the beginning and end of the fertile phase. However, the
monitor could be designed with the current threshold level of the
Persona monitor and thus used without another marker of fertility.

138

Human Fertility: Where Faith & Science Meet

Both the current Persona and the CPFM (with another marker of
fertility) need to be further investigated for their efficacy in helping couples to avoid pregnancy and achieve pregnancy. Protocols for
use of the CPFM with special reproductive circumstances, such as
monitoring fertility while breastfeeding and not ovulating, continue
to be developed.
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